Stepwise approach towards adoption of allergen immunotherapy for allergic rhinitis and asthma patients in daily practice in Belgium: a BelSACI-Abeforcal-EUFOREA statement

Stepwise approach towards adoption of allergen immunotherapy for allergic rhinitis and asthma patients in daily practice in Belgium: a BelSACI-Abeforcal-EUFOREA statement

Abstract Allergic rhinitis (AR) affects 23–30% of the European population with equal prevalence reported in Belgium. Despite guidelines on the correct use of effective treatment, up to 40% of AR patients remain uncontrolled. Allergen immunotherapy (AIT) has been shown to improve the level of control...

Full description

Bibliographic Details
Main Authors: P. W. Hellings, B. Pugin, G. Mariën, C. Bachert, C. Breynaert, D. M. Bullens, J. L. Ceuppens, G. Clement, T. Cox, D. Ebo, P. Gevaert, S. Halewyck, V. Hox, K. Ladha, R. Jacobs, P. Rombaux, R. Schrijvers, K. Speleman, X. Van der Brempt, L. Van Gerven, O. Vanderveken, B. Verhaeghe, K. Vierstraete, S. Vlaminck, J. -B. Watelet, J. Bousquet, S. F. Seys
Format: Article
Language:English
Published: Wiley 2019-02-01
Series:Clinical and Translational Allergy
Subjects:
Allergic rhinitis
Asthma
Allergen-specific immunotherapy
Belgium
Online Access:http://link.springer.com/article/10.1186/s13601-019-0243-1

Internet

http://link.springer.com/article/10.1186/s13601-019-0243-1

Similar Items